Read what’s new on the K2P Blog

• HFpEF Management Update: SGLT2 Inhibitors
• Helping You Deliver Your Best Care to CV Patients – K2P Announcement
• AHA 2022: SPORT Trial Shows OTC Supplements Don’t Beat Statins for Cholesterol-Lowering
• AHA 2022: Trials of New Agents for Resistant Hypertension
• Focus on K2P Faculty: Dr. John Vavalle
• The Illusion of Explanatory Depth and Why CurrentMD Does CME/MOC Better
• Understanding the Difference Between Our Internal Medicine Courses
• Adult Learning Theory with K2P CEO Mary Ellen Beliveau
• 10 Tips for Taking the Cardiovascular Medicine Board Exam
• How to Pass the ECG and Imaging Section of the Cardiology Board Exam
• 8 Tips for Taking the Internal Medicine Boards
• Is it Enough to Just Learn the Blueprint Topics?
• ACC/AHA Issue Report for CV and Non-CV Complications of COVID-19
• The TL;DR on the ABIM LKA
• Dr. Michelle Kittleson – Advanced Heart Failure & Transplantation
• Focus on K2P Faculty: Dr. George Bakris
• ACC 2022: Update on Mavacamten for Obstructive Hypertrophic Cardiomyopathy
• Focus on K2P Faculty: Neil Stone
• ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%
• Electrophysiology Cardiology Legend Dr. Hugh Calkins Interview
• Coronary Artery Disease – Cardiology LEGEND Dr. Deepak Bhatt Explains
• Q&A with Dr. Ty Gluckman – CurrentMD Cardiology
• ACC Issues Guidance on Cardiovascular Sequelae of COVID-19
• FDA Approves Empagliflozin for HFpEF
• K2P eBook: Medical Leaders Identify Critical CME Issues